Department of Public Health and Epidemiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
International Research Center of Excellence, Institute of Human Virology, Abuja, Nigeria.
PLoS One. 2023 Mar 16;18(3):e0282999. doi: 10.1371/journal.pone.0282999. eCollection 2023.
HIV pre-exposure prophylaxis (PrEP) significantly reduces the risk of HIV acquisition. However, studies have demonstrated discordance between self-reported measures and biomedical benchmarks of PrEP adherence. We estimated the correlation between self-reported PrEP adherence and PrEP biomarkers and explored factors associated with adherence among men who have sex with men (MSM) in Nigeria.
TRUST-PrEP, an open-label, prospective study; conducted in Abuja between April 2018 and May 2019. MSM ≥ 18 years with substantial HIV risk were enrolled. Participants reported PrEP adherence in the last month using a 4-point scale from "poor" to "perfect" and serum samples for PrEP biomarkers were collected at months 3 and 9. Serum tenofovir concentration was measured by liquid chromatography-tandem mass spectrometry and considered protective for adherence if ≥ 4.2 ng/ml. Spearman's rank correlation was used to estimate correlation between self-reported adherence and measured tenofovir levels. Generalized estimating equations with a logit link was used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for associations between self-reported adherence and laboratory-measured adherence.
A total of 219 MSM with median age 23 (interquartile range 20-27) years had at least one PrEP biomarker assay. Only 66/219 (30%) had at least one record of protective tenofovir concentration. Correlation between tenofovir and self-reported adherence at 3 and 9 months were 0.1 and 0.02 respectively. Furthermore, 17/219 (8%,) and 49/219 (22%) had serum tenofovir of 4.2-35.4 ng/mL and ≥ 35.5 ng/mL, corresponding to at least 4 and 7 days' PrEP use in a week, respectively. PrEP adherence was higher among participants introduced to PrEP in the clinics compared with communities (aOR: 8.35, 95%CI: [3.24, 21.5]) and those with same-sex practices family disclosure (aOR: 3.60 95% CI: [1.73, 7.51]).
Self-reported PrEP adherence poorly correlated with biomarkers. Facilitating clinic-based PrEP introduction and disclosure of same-sex practices to family among MSM may improve PrEP adherence.
HIV 暴露前预防(PrEP)可显著降低 HIV 感染风险。然而,研究表明,自我报告的措施与 PrEP 依从性的生物医学基准之间存在差异。我们评估了自我报告的 PrEP 依从性与 PrEP 生物标志物之间的相关性,并探讨了尼日利亚男男性行为者(MSM)中与依从性相关的因素。
TRUST-PrEP 是一项开放性、前瞻性研究;于 2018 年 4 月至 2019 年 5 月在阿布贾进行。纳入年龄≥18 岁、有大量 HIV 风险的 MSM。参与者在过去一个月内使用 4 分制(从“差”到“优”)报告 PrEP 依从性,在第 3 个月和第 9 个月采集血清样本进行 PrEP 生物标志物检测。采用液相色谱-串联质谱法测定血清替诺福韦浓度,浓度≥4.2ng/ml 认为有保护作用,提示依从性良好。采用 Spearman 秩相关评估自我报告的依从性与测量的替诺福韦水平之间的相关性。采用对数链接广义估计方程估计自我报告的依从性与实验室测量的依从性之间的关联的调整比值比(aOR)和 95%置信区间(CI)。
共有 219 名 MSM 中位年龄 23 岁(四分位距 20-27 岁),至少有一次 PrEP 生物标志物检测。仅有 66/219(30%)至少有一次记录的替诺福韦浓度达到保护水平。在第 3 个月和第 9 个月时,替诺福韦与自我报告的依从性之间的相关性分别为 0.1 和 0.02。此外,219 名参与者中,17 名(8%)和 49 名(22%)血清替诺福韦浓度分别为 4.2-35.4ng/ml 和≥35.5ng/ml,分别对应每周至少服用 4 天和 7 天 PrEP。在诊所接受 PrEP 介绍的参与者与在社区接受 PrEP 介绍的参与者(aOR:8.35,95%CI:[3.24,21.5])和向同性伴侣家庭披露性取向的参与者(aOR:3.60,95%CI:[1.73,7.51])相比,PrEP 依从性更高。
自我报告的 PrEP 依从性与生物标志物相关性差。促进 MSM 在诊所接受 PrEP 介绍和向同性伴侣家庭披露性取向,可能会提高 PrEP 的依从性。